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Key Points
•We identify genes
prognostic of disease
relapse in patients
allografted for AML.
•Mutational profiles of-
ten change at relapse
postallograft, which
may have implications
for the design of post-
transplant interventions.
Disease relapse is themajorcauseof treatment failureafterallogeneic stemcell transplantation
(allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic
of AML relapse post–allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of
whom relapsed. Two hundred sixty-two mutations were detected in 102/113 (90%) patients.
An increased risk of relapse was observed in patients with mutations inWT1 (P 5 .018),
DNMT3A (P 5 .045), FLT3 ITD (P 5 .071), and TP53 (P 5 .06), whereas mutations in IDH1
were associated with a reduced risk of disease relapse (P 5 .018). In 29 patients, we
additionally comparedmutational proﬁles in bonemarrow at diagnosis and relapse to study
changes in clonal structure at relapse. In 13/29 patients, mutational proﬁles altered at
relapse. In 9 patients, mutations present at relapse were not detected at diagnosis. In 15
patients, additional available pre–allo-SCT samples demonstrated that mutations identiﬁed
posttransplant but not at diagnosis were detectable immediately prior to transplant in 2 of
15 patients. Taken together, these observations, if conﬁrmed in larger studies, have the
potential to inform the design of novel strategies to reduce posttransplant relapse
highlighting the potential importance of post–allo-SCT interventions with a broad antitumor
speciﬁcity in contrast to targeted therapies based on mutational proﬁle at diagnosis.
Introduction
Allogeneic stem cell transplantation (allo-SCT) is an increasingly important treatment in adult acute
myeloid leukemia (AML). Although allo-SCT delivers potent antileukemic therapy through both dose
intensification and the genesis of a potent graft-versus-leukemia (GVL) effect, disease relapse occurs
in 30% to 70% of patients and represents the major cause of treatment failure.1,2 Novel treatment
strategies to reduce disease relapse are therefore urgently required. A number of disease- and
transplant-specific factors such as presentation karyotype, disease status at transplant, and intensity of
conditioning regimen are known to predict relapse risk (RR).3-5 Although mutations in both FLT3 and
NPM1 are prognostic of posttransplant outcome, there has been only limited analysis of the prognostic
impact of mutations in other AML-associated genes after allo-SCT.6 Similarly, there have been no
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studies of changes in clonal structure in longitudinal samples from
diagnosis, from pretransplant, and at relapse. This has hampered
the rational development of novel treatment strategies to reduce
post–allo-SCT relapse.
Next-generation sequencing (NGS) has identified almost all common
recurrent exonic genetic mutations in AML. Importantly, NGS identi-
fied gene mutations prognostic of clinical outcome after intensive
chemotherapy (IC), as well as identifying molecular targets for targeted
therapy.7-11 These studies provided insight into AML clonal structure at
both disease presentation and relapse after IC.12,13 Taken together,
such studies refined risk stratification in IC-treated patients. Given the
distinct kinetic and curative mechanisms in allo-SCT, compared with
IC, it is plausible that different disease-related AML-specific mutations
may be prognostic of relapse post–allo-SCT.
Posttransplant administration of either cellular or pharmacological
therapy represents a key approach to reduce disease relapse after
allo-SCT. Such therapies can augment GVL (eg, donor lymphocyte
infusions [DLI]14 or checkpoint inhibitors15), or manipulate disease
relapse kinetics (eg, FLT3 inhibitors or Azacitidine16-19). Critically,
rational deployment of posttransplant interventions would be aided
by greater understanding of actionable AML mutations in recurrent
disease postallograft, which is currently limited.
To begin to address these deficits, we have characterized genes
prognostic of outcome after allo-SCT and studied clonal structures
at diagnosis and disease relapse.
Patients and methods
These studies were approved by the local institutional review board under
protocol 06/Q1606/110 (MDSBio).
Patients and transplant characteristics
One hundred thirteen patients allografted for AML at 2 major United
Kingdom transplant centers were studied (demographics summarized in
Table 1). All patients provided consent for data collection. Presentation
karyotype was available in 112 patients and was classified according to
Medical Research Council (MRC) criteria.20 One hundred five patients were
in remission at the time of transplant (complete remission 1 [CR1], n 5 78;
CR2, n 5 27). Seventy-five patients were transplanted using a reduced
intensity conditioning regimen according to European Society for Blood and
Marrow Transplantation criteria, and 38 received a myeloablative condition-
ing regimen. Forty-nine patients had disease recurrence with .5% blasts
morphologically posttransplant.
NGS targeted resequencing
Targeted resequencing was performed on 35 genes frequently mutated in
AML and myeloid malignancies on genomic DNA (gDNA) from bone marrow
aspirate (BMA) samples obtained at presentation in all 113 patients. A
similar analysis was performed on BMA samples from 29 patients who
relapsed postallograft. In 15 of these patients, additional samples collected
immediately prior to transplant were subjected to a similar analysis allowing
comparative analysis of genetic mutations at diagnosis, pretransplant, and
relapse. Multiplex polymerase chain reaction (PCR) was performed with 373
amplicons on a Fluidigm Access Array (supplemental Table 1A). Amplicons
covered areas with high frequency of AML gene mutations (hotspots). If
there were no hotspots previously reported in COSMIC (http://cancer.
sanger.ac.uk/cosmic), the entire exon was studied. The exons covered in
each of the 35 genes are listed in supplemental Table 1B. Sequencing was
performed using Illumina MiSeq (300-bp paired-end). Greater than 1.13 105
bases were covered in paired-end sequencing per sample, with an average
read depth of 1339 reads (range 0-3308) per amplicon (supplemental
Table 1A). Technical replicates were performed with 2 amplicon libraries per
sample in independent experiments.
Table 1. Characteristics of patient cohort
Characteristic Number Percentage
Age, y
Age range 16-70
Median age 49
Sex
Male 58 51
Female 55 49
Cytogenetic risk stratification
Favorable risk 5 4
Intermediate risk 85 75
Adverse risk 22 20
Unknown 1 1
Disease status at transplant
CR1 78 69
CR2 27 24
Not in CR 8 7
Relapse posttransplant 49 43
Transplant conditioning
Reduced intensity 75 66
Myeloablative 38 34
Conditioning regimen
Flu/Mel/Campath 58 51
Cy/TBI 29 26
Flu/Mel 9 8
Flu/Cy/TBI 5 4
Bu/Cy 5 4
FLAMSA/TBI/ATG 3 3
FLAMSA/Bu/ATG 1 1
TBI/Flu/Cy/ATG 1 1
Cy/TBI/Campath 1 1
Bu/Flu/Thio/ATG 1 1
Donor source
Sibling 49 43
Unrelated 61 54
Cord 3 3
CMV recipient/donor
Negative/Negative 44 39
Positive/Positive 33 29
Positive/Negative 25 22
Negative/Positive 11 10
Equivocal/Negative 1 1
Status at last contact
Alive 61 54
Dead 52 46
ATG, antithymocyte globulin; Bu, busulfan; CMV, cytomegalovirus; Cy, cyclophosphamide;
FLAMSA, fludarabine, cytarabine, amsacrine, cyclosphosphamide; Flu, fludarabine; Mel,
melphalan; Thio, thiotepa; TBI, total body irradiation.
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Bioinformatics
Sequencing quality was assessed using FASTQC (Samtools) and aligned
using a Burroughs-Wheeler Aligner algorithm in Stampy.21 A Phred score of
30 was set as a minimum quality threshold for variant calling. We used 3
different variant callers: GATK,22 VARSCAN,23 and Pindel.24 As germ line
DNA was not available for analysis, we implemented criteria to optimize
calling of disease-associated mutations and to exclude likely germ line
single-nucleotide polymorphisms or technical artifacts. Inclusion criteria for
variant calling and filtering were as follows: (i) nonsynonymous mutations;
(ii) mutations in protein coding regions; (iii) concordance between techni-
cal replicates; (iv) concordance betweenGATK and VARSCAN; (v) previous
documentation as a somatic mutation in hematopoietic samples in COSMIC;
(vi) novel truncating variants (nonsense, deleterious missense/indels, variants
affecting splicing) not found in human variation databases (ESP6500, 1000
genomes, and dbSNP) with a frequency of .0.0014 (0.14%); (vii) novel
variants not previously reported but occurring in the same codon as a
previously documented somatic variant; (viii) novel variants not previously
reported but occurring within 3 codons of a previously documented somatic
variant. Putative variants were filtered using the following parameters: minimum
coverage 100 reads; minimum variant frequency 0.05; minimum read depth of
variant 5; and P value ,.05. Additional exclusion criteria for variants were the
following: (i) variants predicted to result in a silent amino acid change; (ii)
known polymorphisms present in human variation databases at a population
frequency of .0.0014 (0.14% reflecting the population incidence of myeloid
disease) except for when the variant is a known somatic variant in COSMIC;
(iii) variants not previously noted in hematopoietic disease (documented in,1
hematopoietic samples in COSMIC); (iv) 1-bp indels present adjacent to
regions of.4 homopolymer bases. Putative variants were further validated
by visualization using the Integrated Genome Viewer. Recurrent somatic
variants previously reported in hematological disease in COSMIC but not
in myelodysplastic syndromes or AML were validated by Sanger sequencing.
Identification of FLT3 internal tandem duplication (ITD) by capillary
electrophoresis and NGS
We identified the FLT3 ITD mutation by semiquantitative PCR of gDNA and/
or complementary DNA and fluorescent capillary electrophoresis. Estimates
of FLT3 ITD variant allele frequency (VAF) were made by area-under-peak
analysis. We detected FLT3 ITD by NGS on 60% (26/43) of patients
known to be FLT3 ITD-positive by capillary electrophoresis (supplemental
Table 1C), using primers that were designed to cover exons 13-15 in the
FLT3 gene. We used Pindel in addition to VARSCAN and GATK to improve
the detection rate. We then interrogated the NGS reads for the presence of
the ITD using a sequence specific for that patient’s ITD. Using this method,
we estimated the threshold of detection to be ;0.1% (or 1:1000).
Droplet digital PCR
Our ability to detect mutations with low VAFs by NGS was, on occasion,
hampered by high false positive VAFs (range from ,0.1% to 1.8%; assessed
using wild-type control gDNA). In cases where this background was .0.1%,
droplet digital PCR (ddPCR) improved sensitivity of detection by 10- to 100-fold
(up to 0.002% in our study). ddPCRwas also discriminatory for NGS variant calls
where the NGS VAF was close to (within twofold) the background threshold.
We used ddPCR to look for mutations detected at relapse but apparently
absent or ambiguous at diagnosis and/or CR in 5 patients using the BIORAD
platform.10 Sequences of primers (Thermo Fisher Scientific, Hemel Hempstead,
United Kingdom) and dual-labeled hydrolysis probes (39 fluorescent reporter:
hexachloro-fluorescein–labled probe complementary to wild-type sequence,
6-FAM–labeled probe complementary to mutant sequence; and a 59 quencher:
BHQ-1; Eurofins Genomics, Ebersberg, Germany) are listed in supplemental
Table 1D. gDNA (40-60 ng/well) or whole-genome amplification gDNA
(2 mL/well of a 1:20 whole-genome amplification product, RepliG; Qiagen,
Manchester, United Kingdom) was subjected to ddPCR, and fluorescence of
droplets was analyzed using a 2-color detector (FAM: wild-type/hexachloro-
fluorescein: mutant). Wild-type gDNA was spiked with a mutant control sample
of known VAF to give a predicted VAF of 0.1% as a detection control. Detection
controls for all individual variants were successfully scored mutant with an
average VAF of 0.074% (range 0.044% to 0.102%), whereas all pure wild-type
controls did not show any mutant droplets.
Cytogenetic analysis
Cytogenetic analysis of patient samples was performed at local hospitals by
chromosomal banding analysis (maximum 20 metaphases) and fluorescent
in situ hybridization. Karyotypes were classified using published MRC AML
group criteria as described by Grimwade et al.20
Statistical methodology
Statistical analyses were performed in Stata 14.1. Univariate and multivariate
Cox proportional hazards models were used for the following outcomes:
relapse-free survival (RFS) and overall survival (OS). RR was analyzed using
a competing risks model (Fine and Gray)25 considering death as a competing
risk. Survival analysis was started at date of transplant.
Multivariate analysis included adverse cytogenetics, age, donor source,
transplant conditioning (myeloablative/reduced intensity), disease status at
time of transplant, and cytomegalovirus status of recipient and donor. A gene
mutation was only included in the univariate and multivariate analyses if at least
5 patients had a mutation in that gene. Each gene mutation was assessed
individually with covariables described above. Given the small numbers of
patients with each mutation, P values ,.1 are considered significant in this
exploratory analysis of potential prognostic factors. Forest plots were created
in R and contain all gene mutation hazard ratios for outcome.
Results
Mutation profile of patient cohort at diagnosis
Our patient cohort consisted of AML patients wherein allo-SCT was
offered on the basis of age, performance status, cytogenetic and
molecular risk, and response to induction chemotherapy. We detected
262 mutations in 102/113 (90%) patients (Figure 1A; supplemental
Table 2; supplemental Table 3A). The frequency of mutations in the
studied genes is shown in Figure 1B. The mean number of mutations
per patient in our cohort is 2.3 (median5 3) compared with a mean of
3.4 and 5.2 mutations in the 2 other large published cohorts of 200
and 1540 unselected adults with AML7,11 (Figure 1C). However, as we
used a more limited panel of amplicons, the breadth of coverage of
mutations is less. Therefore, we compared our data with data from
these 2 cohorts curated to mirror the same breadth of genotyping as
we had performed (Figure 1D). This cohort of allo-SCT patients is
significantly enriched for the presence of FLT3 ITD,KIT, TET2,RUNX1,
and SRSF2 mutations and depleted for NPM1 mutations and point
mutations in FLT3 (Figure 1D).
Impact of diagnostic mutational profile on
transplant outcome
Forty-nine patients relapsed after allogeneic transplantation. In
multivariate analysis mutations in WT1 (P 5 .018), DNMT3A
(P5 .045), FLT3 ITD (P5 .071), and TP53 (P5 .06) were associated
with an increased RR (Figure 2A). The presence of a TP53 mutation
was associated with decreased RFS (P 5 .025) and OS (P 5 .007)
(Figure 2B-C). IDH1 mutation was associated with a reduction in RR
(P 5 .018) and improved RFS (P 5 .024) and OS (P 5 .032)
(Figure 2A-C). There was no correlation between the number of
mutations detected per patient and outcome (data not shown).
Genetic characterization of disease
relapse posttransplant
In order to further characterize the molecular basis of disease
relapse after allo-SCT, we next performed mutational analysis in 29
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patients wherein paired diagnostic and relapse samples were
available (Figure 3A; supplemental Table 3B). Changes in genetic
profile (acquisition or loss of genetic or karyotypic abnormalities)
were documented at disease relapse in 23/29 (79%) patients. This
suggests that therapy (either IC or allo-SCT) selects changes in
clonal structure in most patients.
In 13/23 patients, a distinct genetic mutational profile was docu-
mented at relapse, 6 of whom demonstrated concurrent cytogenetic
evolution. Genetic mutations, either not detected at diagnosis or
present at VAF of ,2% (in patients 56 and 112), were subsequently
detected at VAF frequencies of at least 5% in 10/13 patients. In these
13 patients, 7 patients had gains only; 3 had losses only, and 3 had
A
Molecular subgroups of mutations:
NPM1
CpG Methylation
RTK-RAS signaling (PM: point mutation)
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Figure 1. Mutation profile of patient cohort at diagnosis. (A) Heat map detailing mutation distribution among patient cohort with individual cytogenetic risk stratification and
relapse/nonrelapse status post–allo-SCT. (B) Frequency of mutations in the cohort. (C) The number of mutations detected per patient in our cohort. (D) Comparison of our
cohort with 2 published cohorts of de novo AML patients from the Cancer Genome Atlas (TCGA)7 and Papaemmanuil et al11 (Papa). TCGA and Papa datasets were curated to
exclude mutations that would not have been covered by our NGS panel (TCGA-restricted and Papa-restricted). Fisher’s exact test was used to compare frequency of mutations
in the indicated genes between our cohort and the restricted TCGA and Papa cohorts. Genes and frequencies highlighted in blue are those where P , .05.
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gains and losses (Figure 3B). On average, 1.3 additional mutations
were detected at relapse compared with diagnosis. Mutations either
acquired de novo, or selected for, at relapse included the following:
TET2 (n5 4), NRAS,WT1, ETV6, RUNX1, DNMT3A, TP53 (n5 2),
NPM1, IDH1, FLT3 ITD, and PHF6.
We detected change in karyotype alone in 10 patients and, con-
sistent with previous reports, a gain of 4.6 karyotypic abnormal-
ities per patient was observed.26 Of note, 10/23 (43%) patients
with paired karyotyping analysis acquired complex karyotypic
abnormalities (.3) between diagnosis and relapse (supplemental
Tables 4-6).
Genetic characterization of disease at relapse in
comparison with pretransplant characteristics
Next, we asked if genetic mutations detected at posttransplant relapse
were detectable prior to allo-SCTafter IC. If mutations were detect-
able, then pretransplant sampling could be of value in predicting
mutational composition at relapse. Furthermore, mutations detected
prior to transplant and at relapse, but not at diagnosis, are likely
selected by IC.
In 14/29 relapsed patients (11 in CR and 3 not in CR: patients 61,
62, and 84) BMA samples taken immediately prior to transplant were
tested. In another patient (65), we tested a pretransplant sample taken
1 month prior to the patient achieving CR pre–allo-SCT, when the
patient had active disease (;50% blasts). NGS and ddPCR afforded
a detection threshold between ;1:300 (0.35%, range 0.01%-
4.34%) and 1:30 000 (0.003%, range 0.002%-0.013%), respec-
tively. We detected mutations pre–allo-SCT in 9/15 patients
(patients 60, 65: supplemental Table 4; patients 35, 84, 92:
supplemental Table 5; patients 1, 61, 62, 64: supplemental Table 7;
examples shown in Figure 4A-C) with a wide range of VAFs (0.06%-
85.13%). These mutations were previously implicated in preleuke-
mic and leukemic hemopoiesis (ASXL1, DNMT3A, and TET2, IDH2
and NPM1, PHF6, PTPN11, SRSF2, RUNX1, TP53, andWT127-33).
Taken together, this demonstrates a substantial clonal burden
pre–allo-SCT.
In 9 patients where mutations were seen pre–allo-SCT, 3 patterns
of changes were seen. First, in 4 patients, the same genes were
mutated at diagnosis, pre–allo-SCT and relapse (patients 1, 61, 62,
64, supplemental Table 7; examples in Figure 4A), indicating failure
of IC to eradicate clones that subsequently drive relapse post–allo-
SCT. Patients 61 and 62 had persistent disease pretransplant, with
;35% and ;50% blasts, respectively, and additional cytogenetic
anomalies were detected pre–allo-SCT. In patient 61, clones with
t(3;5) and t(5;16) are not present at diagnosis, present pretrans-
plant, and are lost at relapse. In contrast, mutations in NPM1 and
WT1, and the FLT3 ITD, are present at changing VAFs at all time
points. One interpretation is that the cytogenetic abnormalities t(3;5)
and t(5;16) may have been acquired after the mutations. If true,
clones with these karyotypic abnormalities are likely selected by IC
but eliminated post–allo-SCT (Figure 4C).
D
gene
allo-SCT
(n=113)
TCGA
paper
(n=200)
TCGA-
restricted
(n=200)
Fishers
TCGA-
restricted
Papa
(n=1540)
Papa -
restricted
(n=1540)
Fishers
Papa-
restricted
ASXL1 8 (7.1%) 5 (2.5%) 5 (2.5%) 0.0740 71 (4.6%) 62 (4%) 0.1399
DNMT3A 19 (16.8%) 51 (25.5%) 43 (21.5%) 0.3764 362 (23.5%) 323 (21%) 0.3364
FLT3 ITD 43 (38.1%) 39 (19.5%) 39 (19.5%) 0.0005 345 (22.4%) 345 (22.4%) 0.0003
FLT3 PM 7 (6.2%) 17 (8.5%) 17 (8.5%) 0.5153 203 (13.2%) 195 (12.7%) 0.0513
IDH1 13 (11.5%) 19 (9.5%) 19 (9.5%) 0.5664 106 (6.9%) 106 (6.9%) 0.0861
IDH2 14 (12.4%) 20 (10%) 20 (10%) 0.2155 151 (9.8%) 151 (9.8%) 0.4143
KIT 10 (8.8%) 8 (4%) 8 (4%) 0.0833 66 (4.3%) 65 (4.2%) 0.0324
NPM1 17 (15%) 54 (27%) 54 (27%) 0.0168 440 (28.6%) 440 (28.6%) 0.0015
NRAS 12 (10.6%) 15 (7.5%) 15 (7.5%) 0.4029 270 (17.5%) 270 (17.5%) 0.0688
PTPN11 5 (4.4%) 9 (4.5%) 8 (4%) 1.0000 120 (7.8%) 115 (7.5%) 0.3443
RUNX1 17 (15%) 19 (9.5%) 18 (9%) 0.1343 137 (8.9%) 137 (8.9%) 0.0421
SRSF2 11 (9.7%) 1 (0.5%) 1 (0.5%) 0.0001 93 (6%) 92 (6%) 0.1090
TET2 21 (18.6%) 17 (8.5%) 17 (8.5%) 0.0114 156 (10.1%) 155 (10.1%) 0.0104
TP53 6 (5.3%) 16 (8%) 15 (7.5%) 0.6388 101 (6.6%) 101 (6.6%) 0.8421
WT1 8 (7.1%) 12 (6%) 12 (6%) 0.8106 77 (5%) 49 (3.2%) 0.0529
Figure 1. (Continued).
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Second, in 3 patients, mutations detected at relapse were not
present at diagnosis or immediately prior to allo-SCT (patients 25,
35, and 68; supplemental Tables 4-6; examples in Figure 4B),
indicative of clones selected post–allo-SCT. Again there was
heterogeneity in the patterns of mutational change. In patient
35, SRSF2 and IDH2 mutations (VAF 41% to 44% at diagnosis
and CR) were likely clonal heterozygous mutations that persisted
from diagnosis to CR. This is consistent with these mutations
being in preleukemic clones (Figure 4B). At relapse, the VAF
of these mutations dipped to 21%, but mutations in NRAS
A
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Figure 2. Forest plots of RR, OS, and RFS (multivariate
analysis) in our patient cohort. (A) RR per gene mutation in
all patients. (B) OS per gene mutation in all patients. (C) RFS
per gene mutation in all patients. *P , .10. CI, confidence
interval; HR, hazard ratio.
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Q61K andDNMT3AG706Wwere detected at a VAF of 18% to 21%,
consistent with these being markers of a leukemic relapse clone.
In patient 68, the data are most consistent with an NPM1 mutant
leukemic clone that was cytoreduced by IC such that at CR it was not
detected (Figure 4B). At relapse, theNPM1mutant clone reemerged
and 2 TET2 mutations were detected for the first time. However, as
there was ;15% residual donor cells in the relapse sample (inferred
from cytogenetic analysis), we cannot exclude the possibility that the
TET2 mutations were donor derived. Both TET2 mutations have
previously been reported in myelodysplastic syndrome.34
Finally, in 2 patients (65 and 92), complex and distinct changes in
clonal structures occurred from diagnosis to pre–allo-SCT (pre-
sumably reflecting selection by IC or possibly de novo mutation),
and from pre–allo-SCT to relapse (Figure 4C; summarized in
Figure 4D and supplemental Tables 4 and 5).
At diagnosis, 1 interpretation of the data for patient 65 is that there is
at least 1 stem clone with at least 3 clonal heterozygous mutations
(RUNX1 D198G, SRSF2 P95A, and TET2 V1718L: VAF 48% to
56%). In addition, there is a subclonal RUNX1 L175P mutation (VAF
7%). In the intermediate sample taken after the second course of IC
when there was persistent disease (;55% blasts), there is loss of a
subclonewithRUNX1 L175Pmutation, but emergence of a subclone
with PHF6C85X (VAF 25%), which if heterozygous, may be present
in all blasts. There is a difference in the VAF between TET2 (51%) on
the 1 hand and SRSF2 and RUNX1 D198G (34% to 39%) on the
other hand. It is unclear if a difference in VAF between TET2 and
SRSF2 and RUNX1 is due to technical error or if TET2 is present in
.1 clone. At relapse, post–allo-SCT, a TET2Q1084Pmutation (VAF
27%), is detected for the first time, suggesting ongoing clonal
selection, although it remains possible that this variant could be donor
derived. Both TET2Q1084P and trisomy 13 mark the relapse clone.
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Figure 3. Patients with or without genetic changes
between diagnosis and relapse. (A) One hundred thirteen
patients in our study were divided into those who relapsed after
allo-SCT and those who did not. Patients were further classified
according to those where changes to the profile of genetic
aberrations, either in karyotype or in genetic mutations between
diagnosis and relapse. n, number of patients. (B) Graph showing
13 patients who had changes (gains and losses) of the number of
genetic mutations between diagnosis and relapse.
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Figure 4. Graphs showing changes to genetic mutation profile variant at diagnosis, post-IC/pre–allo-SCT, and relapse posttransplant in AML patients. The
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This complex, shifting clonal landscape is also seen in patient 92. At
diagnosis, the following mutations are detected:CSF1RG747R, TET2
H949R (VAF 46% to 47%), and SRSF2 P95L (VAF 72%). As SRSF2
mutations are rarely homozygous, it is possible that the VAF of.50% in
SRSF2 is consistent with an additional copy of mutated SRSF2. The
patient also had an IDH1 R132C mutation (VAF 41%). At CR CSF1R
and TET2, VAFs are unchanged, but the SRSF2 VAF falls to 44%,
concurrent with a loss of the IDH1 mutant clone. At CR, a subclonal
TP53 R136H mutation (VAF 4%) is detected. At relapse, the mutant
TP53 R136H clone expands to likely become clonal (VAF 49%) with a
further likely clonal TP53 P48fs mutation (VAF 50%), which is most
likely on the other TP53 allele. Accompanying this, at relapse, 5 patient
male clones are detected, 4 of which have karyotypic abnormalities
(none of which are complex) together with some residual female donor
cells. In both cases, analysis of sequential samples provides some
insight into potential changes in clonal structure through therapy. In
these 2 cases and in other previous cases, definitive description of
clonal structures requires single-cell genotyping approaches.
Taken together, these sequential mutational snapshots from diagno-
sis to pre–allo-SCT and relapse, on limited numbers of patients, are
highly informative. They show the considerable heterogeneity in
evolving clonal landscapes with selection from diagnosis with IC and
further selection postallograft.
Discussion
The development of novel therapeutic strategies to reduce relapse in
patients allografted for AML is critically dependent on characterization
of the biology of disease recurrence after allo-SCT.We have identified
genes prognostic of disease relapse after allo-SCT. In addition, our
data demonstrate evolution of clonal structure at relapse. Both
observations have implications for clinical practice. We performed
mutation profiling using targeted NGS for recurrent mutations in 35
genes in myeloid malignancy in 113 patients receiving an allo-SCT, 49
of whom relapsed. In contrast to previous studies of patients treated
with IC, this transplant cohort was enriched for FLT3 ITD, KIT, TET2,
RUNX1, and SRSF2 mutations and underrepresented for NPM1
mutations. Although mutations in TET2, RUNX1, SRSF2 are typically
associated with myelodysplastic syndrome and secondary AML, many
patients with a clinical history of de novo AML have mutations in these
genes, and other genes that typically were first identified in chronic
myeloid malignancies.11 Importantly, mutational profiling in secondary
AML, therapy AML and de novo AML, improves the classification
of AML ontogeny.35 Taken together, these data demonstrate the
potential utility of detailed genetic characterization to better charac-
terize AML allo-SCT patient cohorts.
At diagnosis, mutations in WT1, FLT3, DNMT3A, and TP53 are
associated with an increased risk of relapse posttransplant, and
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IDH1 mutations associated with a reduced RR. Both FLT3 ITD and
TP53 mutations have previously been correlated with an increased
risk of relapse after allo-SCT.5,6,36 Furthermore, a similar study (112
patients and resequencing of 26 genes) has recently reported that
mutations inWT1 correlate with an increased RR post–allo-SCT.6 It
is not known if the immunogenicity ofWT1 mutant clones is altered,
but our studies support further evaluation of WT1 mutations on
tumor alloreactivity. Mutations in DNMT3A and FLT3 ITD were
correlated with increased RR but not decreased survival. These 2
genes are frequently mutated in the same patients (7/11 DNMT3A-
mutated relapsed patients also had FLT3 ITD) but are largely
mutually exclusive with TP53 and WT1 mutations, where patients
do have poorer survival. Taken together, this raises the possibility
that DNMT3A/FLT3 ITD patients are more responsive to salvage
therapies. Previous studies of IDH1 mutations on outcome after IC
have reported either no impact on or an increased rate of disease
recurrence.37-39 Therefore, our data demonstrating a reduced risk
of relapse after allo-SCT in patients with an IDH1mutation raise the
possibility that the genetic factors determining outcome after IC
may differ from those determining relapse after allo-SCT.
Caution should be exercised in the interpretation of our data given
our small cohort size. Nevertheless, our data clearly support further
larger studies, which should ideally be prospective. A further
limitation of our study is that, compared with more extensive
genotyping methods (eg, whole exome/ genome sequencing), we
may have failed to identify mutations in less frequently mutated
AML-associated genes, and critically, variants in genes that regulate
immune response. These variants will likely shed important insights
into both GVL and graft-versus-host disease and are likely to be
missed by studies focusing on patients treated only with IC. In this
context, it is of interest that IDH1 mutations modulate DNA
methylation status in leukemic blasts40 and potentially their ability to
be recognized by the donor alloimmune response. Such an argument
may equally apply to other variants that regulate the epigenome.
Our serial characterization of the mutational landscape, albeit in only
15 patients, from diagnosis, to pre–allo-SCT, and at relapse
provides a window on the remarkable heterogeneity of clonal
dynamics during therapy. Despite this heterogeneity, some
principles may be emerging, which need to be validated through
larger studies. First, AML-associated mutations present at diagnosis
were commonly detected prior to allo-SCT (in 9/15 patients who
relapsed). These patients subsequently relapsed with reexpansion
of preexisting clones (4/9 patients), or with evidence of subclonal
selection rather than through development of an unrelated disease-
driving clone (5/9 patients). It is difficult to definitively prove that
emergence of new clones is due to subclonal selection or
acquisition of new mutations from therapy, as it is usually impossible
to rule out selection of minor clones present below the threshold of
detection. However, much of current data supports clonal
selection.41 Second, detection of subclonal change in the BMA
immediately prior to transplant suggests that in some patients
genetic drivers of disease relapse are selected by pretransplant
chemotherapy, which may play an important role in determining RR
posttransplant. It also highlights the potential importance of genetic
analysis immediately prior to transplant, rather than just at diagnosis,
in terms of determining RR. Third, in a proportion of patients,
mutations documented at relapse postallograft were not detectable
at presentation or immediately prior to transplant. Thus, distinct
posttransplant selection pressures may operate in such patients.
These data also confirm that care must be exercised in choice of
genetic markers to detect minimal residual disease (MRD)10 to
monitor outcome posttransplant. Flow MRD, especially quantitation
of leukemic stem cell compartments42 post–allo-SCT, is feasible
and may be a more stable MRD technique in this setting.43 Fourth,
in 10/23 patients whose genetic profile changed from diagnosis to
relapse did so by acquiring a complex karyotype at relapse,
consistent with previous data.26,44 Frequent occurrence of complex
karyotype cells at relapse raises the hypothesis that these cells have
a clonal advantage. Thus, genes that either drive chromosomal
instability or allow a cell to tolerate chromosomal instability are likely
to be important in therapy resistance. Interestingly, not all 10 of
these patients had detectable mutations in TP53, suggesting other
genes may play a role in acquisition or tolerance of a complex
karyotype.
Our demonstration of differences in cytogenetic abnormalities and
genemutations at relapse compared with diagnosis in 23/29 patients
has ramifications for the considerable ongoing work to develop
posttransplant strategies to reduce relapse. These strategies include
either administration of cellular therapies (eg, DLI) to directly augment
GVL or targeted drugs (eg, FLT3 inhibitors) to slow disease growth
posttransplant to provide a longer time period for GVL to develop.
Detection of genetic and cytogenetic changes at relapse but not
diagnosis suggests posttransplant interventions with a broader
antileukemic activity, such as DLI, or checkpoint inhibitors that are
indeterminate of AML genetic and cytogenetic changes may be more
broadly useful. Furthermore, our data caution against the choice of
targeted therapies for administration posttransplant based solely on
the diagnostic mutational profile.
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